Discussing PsA: Risankizumab efficacy across machine learning defined and complex PsA phenotypes

Discussing PsA: Risankizumab efficacy across machine learning defined and complex PsA phenotypes

From The IMID Forum by The Immune-Mediated Inflammatory Disease Forum

February 13, 2026 · 21 min

About this episode

Professor Laura Coates and Phillip Mease discuss the classification of PsA patients using machine learning and GRAPPA terminology.

Join Professor Laura Coates and Phillip Mease as they discuss the top publications in the world of PsA. This month, the conversation covered the ‘classification of patients into distinct PsA phenotypes based on baseline demographics and clinical characteristics using a machine learning approach, and consensus-derived GRAPPA terminology, to support shared clinical decision making, and enable more effective patient stratification in both observational studies and clinical trials.

People in this episode

Host: Professor Laura Coates

Guest: Phillip Mease

Topics covered

  • PsA
  • machine learning
  • patient stratification
  • clinical decision making
  • phenotypes

Keywords

  • PsA
  • risankizumab
  • machine learning
  • patient phenotypes
  • clinical trials
  • observational studies
  • GRAPPA

Mentioned in this episode

Organizations: GRAPPA

Books & works: PsA

More episodes of The IMID Forum

Explore listener stats, chart rankings, contacts and more on the The IMID Forum podcast page.